Results for tag: "Dabigatran Etexilate"

Dabigatran Etexilate is a direct thrombin inhibitor used in the treatment of hematological diseases. It is used to prevent and treat deep vein thrombosis (DVT) and pulmonary embolism (PE). It is also used to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation. Dabigatran Etexilate is a novel anticoagulant that has been approved for use in the United States, Europe, and other countries. Dabigatran Etexilate is a relatively new drug in the hematological drugs market. It is a direct thrombin inhibitor, which means it works by blocking the action of thrombin, a protein involved in the clotting process. This makes it an attractive option for patients who are at risk of developing blood clots. It is also a more convenient option than warfarin, as it does not require regular blood tests or dose adjustments. Some of the companies in the Dabigatran Etexilate market include Boehringer Ingelheim, Pfizer, and Bristol-Myers Squibb. These companies are involved in the research, development, and marketing of the drug. Show Less Read more